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Abstract
Background: Tahyna virus (TAHV) is a human pathogen of the California encephalitis virus (CEV) serogroup
(Bunyaviridae) endemic to Europe, Asia, and Africa. TAHV maintains an enzootic life cycle with several species of
mosquito vectors and hares, rabbits, hedgehogs, and rodents serving as small mammal amplifying hosts. Human
TAHV infection occurs in summer and early fall with symptoms of fever, headache, malaise, conjunctivitis,
pharyngitis, and nausea. TAHV disease can progress to CNS involvement, although unlike related La Crosse virus
(LACV), fatalities have not been reported. Human infections are frequent with neutralizing antibodies present in 60-
80% of the elderly population in endemic areas.
Results: In order to determine the genomic sequence of wild-type TAHV, we chose three TAHV isolates collected
over a 26-year period from mosquitoes. Here we present the first complete sequence of the TAHV S, M, and L
segments. The three TAHV isolates maintained a highly conserved genome with both nucleotide and amino acid
sequence identity greater than 99%. In order to determine the extent of genetic relatedness to other members of
the CEV serogroup, we compared protein sequences of TAHV with LACV, Snowshoe Hare virus (SSHV), Jamestown
Canyon virus (JCV), and Inkoo virus (INKV). By amino acid comparison, TAHV was most similar to SSHV followed by
LACV, JCV, and INKV. The sequence of the GN protein is most conserved followed by L, N, GC, NSS, and NSM. In a
weanling Swiss Webster mouse model, all three TAHV isolates were uniformly neurovirulent, but only one virus was
neuroinvasive. In rhesus monkeys, the virus was highly immunogenic even in the absence of viremia. Cross
neutralization studies utilizing monkey immune serum demonstrated that TAHV is antigenically distinct from North
American viruses LACV and JCV.
Conclusions: Here we report the first complete sequence of TAHV and present genetic analysis of new-world
viruses, LACV, SSHV, and JCV with old-world viruses, TAHV and INKV. Using immune serum generated in monkeys
against TAHV, LACV, and JCV, we have demonstrated cross-neutralization within the CEV serogroup. Such cross
reactivity may complicate virus identification, especially following JCV infection which elicited antibodies that cross
neutralized both LACV and TAHV. These data also suggest that a single vaccine could generate a cross-neutralizing
antibody response which may provide protection against CEV serogroup viruses from a wide geographic range.
Introduction
Tahyna virus (TAHV), family Bunyaviridae, is a mos-
quito-borne pathogen endemic in Europe, Asia and
Africa [1-8]. TAHV is a member of the California ence-
phalitis virus (CEV) serogroup and is closely related to
La Crosse virus (LACV) found in North America [9-11].
Members of this family have tri-segmented, negative-
sense RNA genomes of approximately 13 kb in total
length. The three segments are designated by their size,
small (S), medium (M), and large (L) and are complexed
with nucleoprotein to form three separate nucleocapsids.
The 3’ and 5’ untranslated regions (UTR) are comple-
mentary and highly conserved. The S segment encodes
two proteins: the nucleoprotein (N) and a non-structural
protein (NSs) which inhibits transcription via inhibiting
host cell RNA polymerase II resulting in decreased
interferon (INF) induction [12,13]. The M segment
encodes a single polyprotein (M polyprotein) that is
post-translationally processed into two surface glycopro-
teins (GN and GC) which are the targets of neutralizing
antibodies, and a nonstructural protein, NSM [14]. The
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L segment encodes a RNA-dependent RNA polymerase
[15,16].
TAHV maintains an enzootic life cycle with multiple
culicine and anopheles mosquito species [1,5]. These
mosquitoes feed on hares, rabbits, hedgehogs, and
rodents, which serve as amplifying hosts [5,17-19]. The
virus can overwinter in either virus-infected eggs or live
mosquitoes [5]. During late summer and early fall,
TAHV causes a non-fatal flu-like illness in humans and
is sometimes called “Valtice fever” with symptoms of
fever, headache, malaise, nausea, myalgia, and occasion-
ally bronchopneumonia [4,20]. As with the related
LACV, TAHV disease occurs mainly in children and
can lead to CNS infection. Human infections are fre-
quent with neutralizing antibodies present in 60-80% of
the elderly population in endemic areas [4,20]. In the
Czechland and Slovakia regions, at least 200 documen-
ted cases have been reported since 1963 [5]. It is evident
that the majority of TAHV infections are asymptomatic,
mild, or unreported.
Although TAHV infections are common, limited
research has been done to understand viral genetics or
develop appropriate animal models. We have sequenced
the complete genome of three TAHV isolates and their
biologically-cloned derivatives in order to identify a
TAHV nucleotide sequence associated with wildtype
phenotypes both in tissue culture and in mouse and
monkey models. We also sought to determine the
genetic and antigenic relatedness of TAHV with LACV
and Jamestown Canyon virus (JCV) by cross-neutraliza-
tion using rhesus monkey immune serum. These data
may be useful in identifying vaccine candidates for pro-
tection against this serogroup of viruses.
Results
Sequence analysis of viral genomes
Here we report the first complete sequence of three
TAHV strains including the large (L) segment (GenBank
accession numbers found in Table 1). We first sought to
define a complete genome sequence associated with
wild-type virulence in mice by both peripheral and
intracerebral routes of inoculation, and second, by
sequencing multiple isolates, we sought to determine
the genetic diversity of TAHV isolated in different coun-
tries at different times. All viruses were biologically
cloned to generate a genetically homogeneous prepara-
tion for sequence analysis.
The initial sequence data from TAHV/58/CZ indi-
cated that the original stock vial of this virus was a mix-
ture of two virus populations. Biological cloning was
used to generate pure stocks of both the major and
minor population for sequence analysis and phenotyp-
ing. Genetic comparison of the major population
TAHV/58/CZ-cl(2) and the minor population TAHV/
58/CZ-cl(1) indicated a total of seven synonymous
nucleotide differences and seven non-synonymous
changes (Table 2). TAHV/68/FR and its biological clone
contained identical sequences for each of the segments.
TAHV/84/CZ and its biological clone have a total of
eight synonymous and two non-synonymous differences
in sequence.
The length of the respective S, M, and L genome seg-
ments was identical for each TAHV isolate and con-
sisted of 977, 4490, and 6976 nucleotides. Likewise, the
length of the ORF for each of the predicted proteins N,
NSS, M polyprotein, and L was identical in length and
contained 235, 97, 1140, and 2263 codons, respectively.
TAHV sequence is highly conserved with all viruses
sharing greater than 99% nucleotide and amino acid
identity. The complete TAHV predicted protein align-
ment and consensus sequence can be found in Addi-
tional File 1 pages 1, 2, and 3. The 3’ UTR sequence of
the respective S, M, and L segments was identical (Fig-
ure 1A). The 5’ UTR of each S segment was identical,
with the 5’ UTR of the M and L segments differing by
only two or three nucleotides, respectively (Figure 1B).
Table 1 Passage history and geographic location of isolation of Tahyna viruses used in this study
Virus Strain Site of isolation Passage historya GenBank accession number
TAHV/58/CZ Prototype “92” Bardos Czechoslovakia MB, C6/36 p1 n/ab
TAHV/58/CZ-cl(1)c MB, C6/36 p1, vero p4 HM036208-10
TAHV/58/CZ-cl(2)c MB, C6/36 p1, vero p4 HM036211-13
TAHV/68/FR C14019-29 France MB p5, C6/36 p1 n/a
TAHV/68/FR-cl c MB p5, C6/36 p1, vero p4 HM036214-16
TAHV/84/CZ 22595-6 Czechoslovakia MB p22, C6/36 p1 n/a
TAHV/84/CZ-clc MB p22, C6/36 p1, vero p4 HM036217-19
a Cell/tissue type followed by number of passages. MB = mouse brain, total number of passages unknown.
b Not applicable. Sequence not submitted to GenBank.
c Biologically-cloned derivative.
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In vitro replication kinetics
The kinetics of in vitro replication of TAHV/58/CZ-cl
(1), TAHV/58/CZ-cl(2), TAHV/68/FR-cl, TAHV/84/CZ-
cl was compared in Vero and C6/36 cells. All TAHV
strains exhibit very rapid growth in Vero cells with a
full replication cycle in less than eight hours and titers
reaching near maximum in 24 hours (Figure 2). In com-
parison, TAHV grows more slowly in C6/36 cells with
titers reaching near maximum in 48 hours (Figure 2).
Cytopathic effects (CPE) associated with TAHV infec-
tion of Vero cells consisted of cell rounding and detach-
ment from the flask beginning at 24 hours post-
infection and complete destruction of the monolayer by
72 hours. CPE was not observed in TAHV-infected C6/
36 cells.
TAHV inoculation of mice
TAHV is highly infectious and neurovirulent for weanl-
ing Swiss Webster mice via intracerebral (IC) inocula-
tion with the 50% infectious dose ranging from 0.3 - 1.1
log10 PFU, and all viruses cause disease after inoculation
(Table 3). The ID50 and 50% lethal dose (LD50) are iden-
tical after IC inoculation indicating very little virus, gen-
erally less than 10 PFU, is required to initiate a lethal
infection in mice. However, TAHV is 5 to 5,000 fold
less infectious for mice following intraperitoneal (IP)
inoculation with the ID50 ranging from 1.4 - 4.6 log10
PFU. TAHV/58/CZ-cl(2), TAHV/68/FR (and clone), and
TAHV/84/CZ (and clone) were not neuroinvasive, with
LD50 levels above 5 log10 PFU. TAHV/58/CZ-cl(1) and
the uncloned parental stock both manifest a neuroinva-
sive phenotype not seen with the other TAHV isolates
(Table 3). Since we were able to isolate both a neuroin-
vasive and non-neuroinvasive clone from the same
TAHV/58/CZ parental stock, it is unclear which clone
represents the authentic wild-type phenotype. Previous
work by Janssen et al. [21] also demonstrated differ-
ences in the neuroinvasive phenotype of TAHV isolates
with isolate TAHV/181-57 requiring a very large dose of
virus for the development of CNS disease after periph-
eral inoculation compared to the prototype strain while
both viruses maintained a highly neurovirulent pheno-
type requiring roughly 1 PFU to initiate disease. TAHV/
181-57 was passaged 57 times in mouse CNS tissues
and was no longer able to replicate in non-neuronal tis-
sues both in vivo and in vitro [21,22]. In the present
study, TAHV/58 and THAV/58-cl(2) also appear to be
unable to establish an infection after peripheral inocula-
tion as indicated by the low level of seroconversion in
the IP inoculated groups (Table 3). TAHV/58/CZ-cl(1)
is the only TAHV isolate in this study that was neuroin-
vasive and was found to contain two amino acid differ-
ences from the TAHV consensus sequence (Additional
File 1). TAHV/58/CZ-cl(1) differed from the consensus
at NSM position N346D and at L position D2158N sug-
gesting that one or both of these changes may be
responsible for the neuroinvasive phenotype.
Inoculation of rhesus monkeys with TAHV/58/CZ-cl(1)
Subcutaneous infection of rhesus monkeys with TAHV/
58/CZ-cl(1) generally elicited a strong neutralizing anti-
body response in the absence of detectable viremia
(Table 4). One monkey (DBXJ) had a serum virus titer
of 0.7 log10 PFU/mL on day four post-inoculation and
also had the highest neutralizing antibody level, indicat-
ing that the level of virus replication may correlate with
the level of immune response. One monkey (L22) was
not infected by the virus. TAHV/58/CZ-cl(1) infection
of rhesus monkeys did not result in clinical disease and
all animals remained healthy during the study.
Sequence comparison of members of the California
encephalitis virus (CEV) serogroup
Sequence comparison of the nucleotide sequences of the
S, M, and L segment ORFs of TAHV, LACV, SSHV,
JCV and INKV indicated that these orthobunyaviruses
are genetically diverse with 79-84% identity in the S seg-
ment, 69-73% identity in the M segment, and 74-78%
identity in the L segment compared to TAHV/58/CZ-cl
(1) (Table 5). Comparison of the 3’ UTR (Figure 3A)
and 5’ UTR (Figure 3B) of LACV, TAHV, and JCV indi-
cate considerable diversity in both sequence and UTR
Table 2 Genetic differences between uncloned and
biologically-cloned TAHV
Nucleotide (amino acid) substitution in indicated
segment
Virus S M L
TAHV/58/CZ-cl(2)a No changes T1073A (F338I) T673C
A1097G (N346D) T2191C
T1110C (M350T) T3664C
G1838A (E593K) A5152G
C1846T T5749A
T1920C (F630S) G6533A (D2158N)
A1954C (K631N)
T2995C
TAHV/68/FR-clb No changes No changes No changes
TAHV/84/CZ-clb C729T A2528G (K830E) G1520T (D487Y)
T4468C A2755G
C4469T T4321C
G6820A
A6943T
C6945T
a Genetic comparison between TAHV/58/CZ-cl(1) and TAHV/58/CZ-cl(2).
b Genetic comparison of uncloned parental virus and biologically cloned
derivative.
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length and may be a useful target for PCR-based differ-
entiation of the CEV serogroup.
Sequence comparison of the predicted amino acid
sequences among the serogroup identified the GN pro-
tein as the most conserved (Table 6, Figure 4). Although
the L protein was quite divergent, sharing 83-90%
amino acid identity, the six primary structure motifs
common to RNA-dependent RNA polymerases were
highly conserved, suggesting sequence conservation
among functional regions of the protein (Figure 5, 6)
A
S segment 3’ untranslated region (nt 1-78). 
        1 
TAHV/58/CZ-cl 3’ .............................................................................. 5’ 
TAHV/68/FR-cl 3’ .............................................................................. 5’ 
TAHV/84/CZ-cl 3’ .............................................................................. 5’ 
Consensus     3’ AGTAGTGTACTCCACTTGAATACTTTGAAAATAGTTTGTCATTACTTGAGATACCGAGAGGAATAACTTGGAAGTGTG 5’ 78 
M segment 3’ untranslated region (nt 1-61) 
        1 
TAHV/58/CZ-cl 3’ ............................................................. 5’ 
TAHV/68/FR-cl 3’ ............................................................. 5’ 
TAHV/84/CZ-cl 3’ ............................................................. 5’ 
Consensus  3’ AGTAGTGTACTACCAAGTATAGATAACGTTTGAAGATTAAAGTCAATTCACAAGTTCCAAG 5’ 61 
L segment 3’ untranslated region (nt 1-61) 
        1 
TAHV/58/CZ-cl 3’ ............................................................. 5’ 
TAHV/68/FR-cl 3’ ............................................................. 5’ 
TAHV/84/CZ-cl 3’ ............................................................. 5’ 
Consensus     3’ AGTAGTGTACTCCTATCTACAAAACTTACAAAAACTTTAGTTTGAAACCAATATATGTATC 5’ 61 
B
S segment 5’ untranslated region (nt 784-977) 
                   784 
TAHV/58/CZ-cl  3’ .................................................................................................... 5’
TAHV/68/FR-cl  3’ .................................................................................................... 5’
TAHV/84/CZ-cl  3’ .................................................................................................... 5’
Consensus      3’ TAAATGGGATTAAGTCTGTAATTAGGCTCAAAATTCAAAATTTTATTGTAATAATTTGGTCATAATTGGCTATCCAAAAGGGTTCCCCAAGAGCCCACAA 5’
883 
 
         884 
TAHV/58/CZ-cl  3’ .............................................................................................. 5’ 
TAHV/68/FR-cl  3’ .............................................................................................. 5’ 
TAHV/84/CZ-cl  3’ .............................................................................................. 5’ 
Consensus      3’ TAATAGCAGCTAAATGGGTGGGTGGTAGGGGACAGCAAAAAAATAGAAGTTAGATCATTTATTTTATAAAAGGTATTCAGTGGAGCACACTACT 5’ 977 
M segment 5’ untranslated region (nt 4382-4490) 
          4382
TAHV/58/CZ-cl  3’ .......................................................................................C............ 5’
TAHV/68/FR-cl  3’ .................................................................................................... 5’
TAHV/84/CZ-cl  3’ ......................................................................................C............. 5’
Consensus      3’ TAAGGAGCATAGCTGCTAAGGAATTGGGGTTTAGATATTAAGGGGAGGGGGGCTAACAACAGCGTAATCTATTTGACAAACATTATTTTATACTTGGTAG 5’
4481 
 
         4482 
TAHV/58/CZ-cl  3’ ......... 5’ 
TAHV/68/FR-cl  3’ ......... 5’ 
TAHV/84/CZ-cl  3’ ......... 5’ 
Consensus      3’ CACACTACT 5’ 4490 
 
 
L segment 5’ untranslated region (nt 6851-6976) 
                   6851 
TAHV/58/CZ-cl  3’ ................................................A................................................... 5’
TAHV/68/FR-cl  3’ .............G............G......................................................................... 5’
TAHV/84/CZ-cl  3’ .................................................................................................... 5’
Consensus      3’ TAAACAATAGAGTATAGTTTTATTATTTCAAATCTAAATTCCAAATTTGTAGGGTTGAATTGGGGCTAATTGGGGTTAGGGCAAATAACAGCTATTGTAT 5’
6950 
 
         6951 
TAHV/58/CZ-cl  3’ .......................... 5’ 
TAHV/68/FR-cl  3’ .......................... 5’ 
TAHV/84/CZ-cl  3’ .......................... 5’ 
Consensus      3’ AGATTTGTAGATAGGAGCACACTACT 5’ 6976 
Figure 1 Alignment of 3’ (A) and 5’ (B) untranslated regions of the S, M, and L genome segments of TAHV (cDNA presented). for each
genome segment the consensus sequence consists of two or more sequences sharing the same nucleotide at a given position. Underlined
sequence indicates region known to be conserved among orthobunyaviruses. Since differences in the 3’ or 5’ UTR of TAHV/58/CZ-cl(1) or TAHV/
58/CZ-cl(2) were not observed, only one sequence is presented.
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[16]. Amino acid identity was lowest among the non-
structural proteins, with NSS and NSM sharing 70-71%
identity and 65-75% identity, respectively (Table 6,
Figure 7).
Antigenic relatedness of three CEV serogroup members
To understand the level of antigenic relatedness between
CEV serogroup members TAHV, LACV, and JCV, we
used rhesus monkey immune serum for cross neutrali-
zation analysis. Monkeys were immunized with 105 PFU
biologically-cloned LACV/78/NC-cl, JCV/61/CO-cl, or
TAHV/58/CZ-cl(1) and serum was collected 28 days
post-inoculation. Each of the three immune sera
strongly neutralized the homologous immunizing virus
(Table 7). TAHV immune serum weakly neutralized
LACV and only minimally neutralized JCV. LACV
immune serum weakly neutralized TAHV and did not
neutralize JCV. However, JCV immune serum is unique
and was capable of cross neutralizing all three viruses
(Table 7). Calculations of antigenic relatedness indicate
these three viruses, although all members of the CEV
serogroup, share less than 6% antigenic relatedness
(Table 8). Serological assays based on virus neutraliza-
tion that are used to identify viruses of the CEV ser-
ogroup could be complicated as a result of the broad
cross-neutralizing ability of JCV.
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Figure 2 Growth kinetics of TAHV in Vero and C6/36 cells. Replication of TAHV/58/CZ-cl (1), TAHV/58/CZ-cl (2), TAHV/84/CZ-cl, and TAHV/68/
FR-cl in Vero cells or C6/36 cells infected at an MOI of 0.01. All viruses demonstrated rapid growth with a complete replication cycle in both cell
types in less than 8 hours.
Table 3 Tahyna virus is highly infectious and neurovirulent for weanling Swiss Webster mice, but strains differ in
neuroinvasiveness
Neuroinvasivenessa (log10PFU) Neurovirulence
b (log10PFU) Phenotype
e
Virus LD50
c ID50
d LD50 ID50 Neuroinvasive Neurovirulent
TAHV/58/CZ 3.5 3.5 0.5 0.5 Low High
TAHV/58/CZ-cl(1) 1.5 1.4 0.7 0.7 High High
TAHV/58/CZ-cl(2) >5 4.5 0.8 0.8 Low High
TAHV/68/FR >5 4.4 0.7 0.7 Low High
TAHV/68/FR-cl >5 2.6 0.9 0.9 Low High
TAHV/84/CZ >5 4.6 1.1 1.1 Low High
TAHV/84/CZ-cl >5 3.5 0.3 0.3 Low High
a Groups of weanling Swiss Webster mice (21-23 days old) were inoculated intraperitoneally with 100 μL of diluted virus (0 - 5 log10 PFU).
b Groups of weanling Swiss Webster mice (21-23 days old) were inoculated intracerebrally with 10 μL of diluted virus (1 - 4 log10 PFU).
c LD50 = Lethal dose 50%.
d ID50 = Infectious dose 50%.
e Neuroinvasive phenotype: Low = LD50 ≥ 3.5 log10 PFU; High = LD50 ≤ 1.5 log10 PFU. Neurovirulent phenotype: High = LD50 < 1.5 log10 PFU.
Bennett et al. Virology Journal 2011, 8:135
http://www.virologyj.com/content/8/1/135
Page 5 of 14
Conclusions
Genetic analysis of three complete TAHV genomes has
demonstrated a high level of conservation (99%) at the
nucleotide and amino acid level, despite the fact that
the viruses were collected from temporally distinct
regions spanning a 10 to 26 year period. This level of
genetic stability is remarkable and suggests a strong
environmental pressure to maintain specific genetic
compositions. In nature, the level of genetic stability
may be even greater than reported here due to the like-
lihood that genetic changes may have arisen during in
vitro passage of the virus following isolation. A similar
level of amino acid sequence conservation was also
observed with North American LACV, which maintains
a more diverse nucleotide sequence (75-87%), but a
strict amino acid conservation (90-98%) [23]. We have
hypothesized that the unique ecological niche that each
CEV serogroup member occupies controls the protein
sequence to a greater extent than the nucleotide
sequence. This allows for constant drift at the nucleo-
tide level but selection against viruses that are less fit
during one or more of the transmission steps. Sequence
analysis of additional TAHV strains isolated from multi-
ple insect vectors or amplifying hosts would further elu-
cidate the genetic diversity of TAHV strains.
The virulence phenotype of TAHV is somewhat differ-
ent in weanling mice than that observed for JCV and
LACV. Although all of these CEV serogroup viruses
possess a high level of neurovirulence when inoculated
directly in brains of mice, JCV and TAHV are generally
less neuroinvasive than LACV [24], although a single iso-
late, TAHV/58/CZ-cl(1), displayed a level of neuroinva-
siveness similar to that observed for LACV. The
relevance of these mouse phenotypes to the actual ence-
phalitogenic potential in humans is uncertain. When
inoculated into non-human primates by a peripheral
route, LACV, JCV, and TAHV elicit a robust neutralizing
antibody, even in the absence of detectable viremia, as is
the case with LACV and TAHV. Inoculation with JCV
produced a brief, but significant level of viremia, as high
as 103 PFU/ml in rhesus monkeys [24]. Nevertheless,
none of the 24 monkeys inoculated with these viruses
displayed any clinical signs of disease. Historically, there
is little or no experience with experimental inoculation of
non-human primates with the CEV serogroup viruses, so
it remains unclear how well these animals mimic the
infectious process in humans. However, for humans the
sero-prevalence of TAHV is high in endemic areas, but
the incidence of clinical disease is remarkably rare. Non-
human primates may be accurately reproducing this low
incidence of clinical disease, however inoculation of a
large number of monkeys would be necessary to observe
the infrequent clinical disease if it occurs at all in non-
human primates.
We isolated two distinct biological clones from the par-
ental TAHV/58/CZ stock, and these clones differed in
their level of neuroinvasiveness. Only two amino acid dif-
ferences were noted between the neuroinvasive clone,
TAHV/58/CZ-cl(1), and the consensus sequence derived
from the other TAHV isolates. Individual differences
found in the NSM and L proteins suggest that one or both
of these changes resulted in the ability of this virus to
cause CNS disease in mice after peripheral inoculation.
We have previously shown for LACV, that a single amino
acid change in the GN protein abrogated the neuroinvasive
phenotype in mice [25]. As an initial step in the develop-
ment a vaccine against the CEV serogroup, we sought to
understand the genetic and antigenic relatedness of
TAHV, LACV, and JCV. The attachment glycoprotein GN
found on the surface of the virion was the most conserved
among these orthobunyaviruses suggesting a strongly con-
served function, such as tropism for both vertebrate and
invertebrate tissues, or the ability of the protein to escape
Table 4 Tahyna virus TAHV/58/CZ-cl(1) is immunogenic in
rhesus monkeys in the absence of viremia
Monkey
Number
Peak virus
titera (log10PFU/mL)
Neutralizing antibody titer
on indicated dayb
0 42
DBPN <0.7 <10 2673
DBM6 <0.7 <10 1472
A5E006 <0.7 <10 244
DBXJ 0.7 <10 8379
A5E036 <0.7 <10 1284
L27 <0.7 <10 64
L22 <0.7 <10 <10d
DC11 <0.7 <10 701
GMTc: < 10 896
a Serum was collected on days 0, 2, 4, 6, 8, 10, 14, 21, 28, and 42. Viremia was
detectable only on day 4 in one monkey. Lower limit of detection is 0.7
log10PFU/mL.
b Reciprocal PRNT60 against TAHV/58/CZ-cl(1). Lower limit of detection is 10.
c Geometric mean neutralizing antibody titer.
d Monkey considered uninfected and PRNT not used in GMT calculation.
Table 5 Nucleotide identity of the orthobunyavirus S, M,
and L segment ORFs compared to prototype TAHV/58/
CZ-cl(1)
Percent nucleotide identity
Virus S M L
LACV/78/NCa 84 73 77
SSHV/59/MTb 84 73 78
JCV/61/COc 79 69 74
INKV/64/FId 80 69 74
a GenBank accession number EF485036 - EF485038.
b GenBank accession number EU294510, EU262553, EU203678.
c GenBank accession number HM007350 - HM007352.
d GenBank accession number U47137, U88059, EU789573.
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immune selection pressures. Monoclonal antibody raised
against the GN protein of LACV was able to bind to
TAHV and JCV as well, indicating that some epitopes may
be shared among these viruses (data not shown). The
other attachment glycoprotein, GC, was more diverse, but
the majority of the diversity was found in the first 400
amino acid residues of N-terminus of the protein. The
conservation of these proteins did not translate into cross
neutralization for all species. JCV was an exception with
infection resulting in a unique broad cross-neutralizing
antibody response. However, it has been reported that
while mouse antiserum raised against TAHV or Lumbo
virus was able to cross-neutralize each virus, serum sam-
ples from humans naturally infected with one virus do not
reciprocally neutralize the other virus to a significant
extent [26]. In the current study, we used primate sera
from rhesus monkeys to demonstrate the cross-neutraliz-
ing potential of JCV serum, with the expectation that this
A
S segment 3’ untranslated region
      
LACV/78/NC-cl 3’ .................................A.....TG..G...G.TTTT....T.A.G....ATTA.CAAG...GTG 5’ 
TAHV/58/CZ-cl 3’ .................................GT....C...-...-.GAGA......-........A..T.GA...GTG 5’ 
JCV/61/CO-cl 3’ ............................G....T....AA..AA..CCC----..TA..--.......C..G.TTGA.--- 5’ 
Consensus  3’ AGTAGTGTACTCCACTTGAATACTTTGAAAATANATTGTNATTNACTNTNNNNTACCGANGAGGAATANCTNGNNAGTNNN 5’ 81 
M segment 3’ untranslated region 
 
LACV/78/NC-cl  3’ ...........................................T..GAAT....GC.A... 5’ 
TAHV/58/CZ-cl    3’ ..................................G.........AAT.CA...G.T.C... 5’  
JCV/61/CO-cl 3’ .......................A......CA...C...---....A.TC.....------ 5’ 
Consensus  3’ AGTAGTGTACTACCAAGTATAGATAACGTTTGAATATTAAAGTCTTNTNNCAAATNCNAAG 5’  61 
L segment 3’ untranslated region 
 
LACV/78/NC-cl  3’ ..............................G...A..C...CAT..CA.A.....C.C..A 5’ 
TAHV/58/CZ-cl    3’ .....................................T.......AA........T....C 5’ 
JCV/61/CO-cl     3’ ................T...............T..AAATAA...C.-.TT.....AC.--- 5’ 
Consensus  3’ AGTAGTGTACTCCTATCTACAAAACTTACAAAAACTTNAGTTTGATNCCAATATANGTATN 5’  61 
 
 
B
S segment 5’ untranslated region
      
LACV/78/NC-cl  3’ ------.........CAT--G..G..T..GA..C....-.........C-......AC..A.G........A.--............T..........T. 5’ 
TAHV/58/CZ-cl    3’ ------.....-......--.....T...--......C-..A......A-........T.G.AA........TCA.......C....C.........C.. 5’ 
JCV/61/CO-cl     3’ TAAACAA......CA..GGC.TT......AT...T.A.A.A......GGT.........AT.T.A..A.....TCA....CA..T.TAT..TT..C...T 5’ 
Consensus     3’ NNNNNNTAAATAGGGATTNNAAGTCAGTANNATTAGGTNTCTAAATTCNNAAATTTTAATNTNTTAATTTGGTNNTAATTGGTTATCNAAAAGGGTTTCC 5’  100
 
LACV/78/NC-cl  3’ TT....G----...................................................C..T..A.........AA..AA................ 5’ 
TAHV/58/CZ-cl    3’ C..--.-----.........T...............................................G.T..A.....T....T......G........ 5’ 
JCV/61/CO-cl     3’ A.....TCTTATGA...T...C........AC..........................CTT......TC..........G.....G.T............ 5’ 
Consensus     3’ NAAAGGNNNNNAGCCCACAAAAATAGCAGCTAAATGGGTGGGTGGTAGGGGACAGCAAAAAAATAGAANTCAGGTCATTNATTTAATAAAATGTATTCAG 5’  200
 
LACV/78/NC-cl  3’ .............. 5’  
TAHV/58/CZ-cl    3’ .............. 5’ 
JCV/61/CO-cl     3’ .............. 5’ 
Consensus     3’ TGGAGCACACTACT 5’  214  
M segment 5’ untranslated region
 
LACV/78/NC-cl 3’ TAGGGAATCTATGCAGAATAAA...G.GTC.T.T..T..........T.T.TA.C....CT...G...---.G.GG....T....AA............- 5’ 
TAHV/58/CZ-cl    3’ -----------------------------.A..G.GC...GC.GC...G----.A..T.GG....AG.T--....A....A.....G............- 5’ 
JCV/61/CO-cl  3’ --------------------TG...C.CA....CT.G.G...G.A....A.ATTT.A..TA......GGGTT...T....GT....TTA.....A.CT.C 5' 
Consensus  3’ NNNNNNNNNNNNNNNNNNNNNNATTNANNTCAGNATNATATATTCTAATNGNNGNATAGNNGTTTTTANNNATTANGGGGNGGGGGNCTAACAACAGCGN 5’  100
 
LACV/78/NC-cl  3’ ...A........G...........T..................... 5’ 
TAHV/58/CZ-cl    3’ ...-.C.....G............C..................... 5’ 
JCV/61/CO-cl 3’ .G.G.........G..T....TAAA..................... 5’ 
Consensus  3’ TAANTTTATTTTACAAACATTATTNTATACTTGGTAGCACACTACT 5’  146 
L segment 5’ untranslated region
 
LACV/78/NC-cl  3’ –T.G..G.TAT.......C.G--..A.C.GAC....AGGC.ATA..T..GGG.......TG.A......CTAAG...C...AA.-....GG.T....... 5’ 
TAHV/58/CZ-cl    3’ .A.AC....--....A...T.TT.T....TC....C......CC..A...A.......G----........C.....GGGGT.--....CA......... 5’ 
JCV/61/CO-cl     3’ .G.T.C.C.TCAGC..G....--.....AAT.G.......G.---.G...T.G..T...AT.GGGG.....T...ACA...C..CT.A.TTT..TTT..- 5' 
Consensus  3’ TNANTAATANNGAGTTTAGATNNAGTATTNNAAATTTAAATTNNAANTTTNTAGGGTTTNNGNAATTGGGGNTAATTNAAANTGNAGGGNNAATAACAGC 5’  100
 
LACV/78/NC-cl  3’ ..C............................... 5’ 
TAHV/58/CZ-cl    3’ T........G........................ 5’ 
JCV/61/CO-cl     3’ ...CA.T.....A.--.CT.G.T........... 5’ 
Consensus  3’ AATTGTATAAATTTGTAGATAGGAGCACACTACT 5’  134  
Figure 3 Alignment of the 3’ (A) and 5’ (B) untranslated regions of LACV/78-cl, TAHV/58/CZ-cl, and JCV/61/CO-cl. Sequence identical to
the consensus indicated with a (.), areas where no censuses exist indicated by (X), gaps indicated by (-).
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would more closely mimic the antibody response in
humans. Inclusion of the JCV GN and GC proteins in a
CEV serogroup vaccine may result in strong cross protec-
tive immune response against viruses found in both North
America and Europe, and possibly other regions.
Here we report the first complete genome sequence of
TAHV and genetic analysis of complete genomes of
new world LACV, SSHV, and JCV with old world
TAHV and INKV. As additional virus isolates become
M polyprotein                 G
N
TAHV/58/CZ-cl  --.MFV.FF...S......................Q....................FR.....Y.....................V..............  
SSHV/59/MT              --..C..I.F.V..................................................V.S.....................T.............  
LACV/78/NC-cl  --..R..V...V............................................VR....V.S.....................I.........S...  
JCV/61/CO-cl  MEVLNLI..L..CS....F.....................................V..T.......I.M.....A.......Q.S..............  
INKV/64/FI              MEVLNLI..LT.CS....F........................................T.......I.M.....A.......Q.S..............  
Consensus   XXMIXILWLIALTAASPVYQRCFQDGAIVKQNPSKEAVTEVCLKDDVSMIKTEARYIKNATGTFANNVAIRKWLVSDWHDCRPKKISGGHINVIEVGDDL  100 
 
TAHV/58/CZ-cl  T....A...N..........................................................................................  
SSHV/59/MT              ....................................................................................................  
LACV/78/NC-cl  .....................................................................V..............................  
JCV/61/CO-cl  .......I.....V.T.......I.....N.....V................................................................  
INKV/64/FI              .......I.....V.T.......I.....N.....V................................................................  
Consensus   SLHTESYVCSADCTIGVDKETAQVRLQTDTTNHFEIAGTTVKSGWFKSTTYITLDQTCEHLKVSCGPKSIQFHACFNQHMSCVRFLHRTILPGSIANSIC  200 
 
TAHV/58/CZ-cl  ..V.....TV...........................L.....V........................................................  
SSHV/59/MT              ....................V............V......A...................................D.......................  
LACV/78/NC-cl  ........................................M...................................D.......................  
JCV/61/CO-cl  ...........S.V.......V....V............F...WV.......................................................  
INKV/64/FI              ...........S.V...F.T.V....V................W........................................................  
Consensus   QNIEIIILVTLTLLIFILLSILSKTYICYLLMPIFIPIAYIYGIIYNKSCKKCKLCGLVYHPFTECGTHCVCGARYETSDRMKLHRASGLCPGYKSLRAA  300 
     NS
M
 
TAHV/58/CZ-cl  ................................A.DTQ.T.K......N..S..MK..M..IM.M.......S...CA......................H 
SSHV/59/MT              ..............V...I..........S..V...K...E..Q......D..L.I.F..FV..M.......L.I.....G..........S.L......  
LACV/78/NC-cl  ....................V........S..L...K.T.E..E.........S.I.S..FT..L....S..LVI....TG............I......  
JCV/61/CO-cl  ...............M..I.........S.......S..YT.D...N..VQ..E......Q.I....G...A.L.L..IL.YF......K..........  
INKV/64/FI              ...........V...M............S.......S..YT.G......V...E......Q.I....SI..V.L.L..I..YF.R.......S......K  
Consensus   RVMCKSKGPASILSIITAVLILTFVTPINAMVIGESXEVFXLEDLPDDMLEMAXRVNIYYXICIINYAVTWGFILIGLLIALLFKKYQHRFLNFYAMYCE  400 
                       G
C
 
TAHV/58/CZ-cl  .............NE....................LT.........Q..S..LT....V..I.M.....V.I.H.D....EK.S..AD............  
SSHV/59/MT              ............RN..................T...T.........R.....VM....A.M..T.....AI..Q......TT.LETEN.N..........  
LACV/78/NC-cl  .......K....RH......................A.........Q.....MM.......F.......AI..Q......TT.LETES.D..........  
JCV/61/CO-cl  ......EK...THW..............F..V....I.K.S............RDI....LAM........F.G.S....AA....KVV...........  
INKV/64/FI              ......E.A..T.W..............F..VT...V.K.S...II.......RDM..T.L.IM.......F.G.T....AA....KTV...R.......  
Consensus   ECDMYHDRSGLKYXGDFTNKCRQCTCGQYEDAAGLMXHRKTYNCLVKYKAKWIXNFLIIYILLILIKDSLLVVXAAGTDFXXCIDEXXITWNCTGPFLNL  500 
 
TAHV/58/CZ-cl  ...E.K....S.N.........D.......S..S...E.......F...QRSY...............................................  
SSHV/59/MT              ...Q.Q....P.A.........Q......M...AS..E...........K..............S......A..S...................D.....  
LACV/78/NC-cl  ...Q.Q....P.T.........K........I.TR..............R.D......T.....SK........S.........................  
JCV/61/CO-cl  .R...S...AS.AG..D.....GV.........KNM..E.S.S.K..DSL..Y.E.......F..........Y.........V..T.......G..VV.  
INKV/64/FI              .R...SQ..TG.TD..D.....G..........K.M..E.S.S.KC.DDL..H.E.......F..........Y.........V..T.......G..VV.  
Consensus   GNCDKXQKKEXYXNIATQLKGLXAISVLDIPMIXKIPDDIAGALRYIEEXETFHVQLTAEYAMLTRYCDYYTQFTDNSGYSQTTWRVYLRSHDFEACILY  600 
 
TAHV/58/CZ-cl  ...........................N......S..........MS..........F...KL.KE.K.E..VT.AE...G.Y.............K..E  
SSHV/59/MT              ...................R.......NY.....N..........M...............T..S..S.....A.TN...E...........V.......  
LACV/78/NC-cl  ...N......N.E..............DY.P..............T...............T..S..S.....A.TN...T..................K  
JCV/61/CO-cl  ..........Y....N.AK........T..T.QKV..N........V..K.....GT..V.EAM.R.D.GSMAHF.LE.RK...T....A.L....V.LQ  
INKV/64/FI              ...............N.AK........T..T.QK...N........V..K.....GTS...ESM.R.D.RSMTHF.LE..K...T....T.L....S.LQ  
Consensus   PNQHFCRCVKHGDKCSSSNWDFANEMKXFYSGKQAKFDKDLNLALLALHHAFRGTSSAYIAXMLAKKXNDDLIXYAXKIKXKFPGNALLKAIIDYIAYMX  700 
 
TAHV/58/CZ-cl  D.T..NN.....M....IFEVP.....S-..RL.-S..D..TN.N.NPSHI...I.T.........VS..........SQ..I....DSQ.......QT.  
SSHV/59/MT              ..S..SS.....F...L...SA...A.SLS.GS.-P.....LV...RS..S.....S.........VS........D.NG.......SDG.......Q.T  
LACV/78/NC-cl  ..PG..N.....F..EL....N.A.ASNLA.GK.-S.....L.I..KS..T.....DVA........IYA........NG.......SGG....ST...I  
JCV/61/CO-cl  ..G.I...EL..D.E..K...E..E.TPQV.SHRNDQ....N.E.NSDT......QK.L.I....K.KFEN......H......MM.NVSIY...SE...  
INKV/64/FI              .PA..S..EL..D.E..K...E..E..Q-L.SHRTDQ....N.D.NSNV.....IQK.S.I....R.KFEN......H......TM.NVSIY...SE...  
Consensus   SLXEMATFKYDEXWDDFLYKPXPTKSPXXIRXXEXXSYNFKXAVSSXXIKVCKNVKXVVCLSPRSGAXYDSIIACGEPANPSVYRKPXXXVFQSNADRSH  800 
 
TAHV/58/CZ-cl  F..S.T....N..T.GE.II..........T.FTEY.QF.....V.........E.T.TT........D............................N..  
SSHV/59/MT              ..........DF...SQ.E...........A..P.VK.S.LT..VK............AA......Q.................T..........G...V  
LACV/78/NC-cl  ...L.......F.AISQ.E...V.......I..S.VKPLQEGN.TK............AT....V.Q.................T.....Y....G.T.V  
JCV/61/CO-cl  ..I.......K....ET...N.L......AK.MD....H..........I..T.....QE.D.T.V....GNY....VH........V.........T..  
INKV/64/FI              ..I............ET...N.L......AR.MD..V.H..V..........T.....QE.D.T.V....GNY....AHR.......V............  
Consensus   YCLADSHCLEEYEVVXXELLDAIKKSKCWEXEYXDIILXKQSDGLRSCRMKDSGNCNVXXNRWPIILCENDKFYYSELQKDYDKDQDIGHFCLSPRCSTI  900 
 
TAHV/58/CZ-cl  .H...R......T.....NN....E......L...............T....S..........M....................................  
SSHV/59/MT              .F...P......N....R...A.....NI...D...................................................................  
LACV/78/NC-cl  .....P......N....R...A.....NI..........................................................V............  
JCV/61/CO-cl  ....S.R..KK.E..I...T....S.Q..A.........S........I...VR.........A.....V..V..I....N.F...........A.....  
INKV/64/FI              ....S.R..K..D..I...T....S.Q..A.........S........I...V..........A.....V..V..V....N.F...........A.....  
Consensus   RYPINKKHISNCXWQVSHSSIDKIDVHELEDIEQYKKAITQKLQTSLSLFKYAKTKNLPHIKPIYKYITIEGTETAEGIESAYIESEIPALAGTSIGFKI  1000
 
TAHV/58/CZ-cl  T..S...............................V.............VNVP.GT......................I................I....  
SSHV/59/MT              T....................SI..........S................K.N.QT......................I.............R.......  
LACV/78/NC-cl  ............A........S..A...S....S................N.N.QV.....................................E..S...  
JCV/61/CO-cl  ..R..NY.M.................................K.......I.D.KD.....S.....T............................A...  
INKV/64/FI              ..R..NY.M........G....T.....I......V......K.......I.D.KE.......G...T............................A.H.  
Consensus   NSKEGKHLLDVIGYVKSASYSAVYTKLYTTGPTIGINTKHDELCTGPCPAXIXHXXGWLTFAKERTSSWGCEEFGCLAVSDGCVFGSCQDIIKDELTVYR  1100
 
TAHV/58/CZ-cl  .....T.........A................DQ.........A........VR....M......I..............N...................  
SSHV/59/MT              ...D.....................P.......L.........T......V..Q.....I..V...................V.................  
LACV/78/NC-cl  .........................PV......L.........T......V.VQ.....I......................V......R..........  
JCV/61/CO-cl  .T...L.T.........................K...........T...V.....................................S.R..........  
INKV/64/FI              .T...P.T.........................K...........T................................I........L..........G.  
Consensus   KETEEVTDVELCLTFSDKTYCTNLNAITPIITDXFEVQFKTVESYSLPRIIAIKNHEIKVGQINDLGVYSKGCGNVQKVNGTNYGNGVPKFDYLCHLASR  1200
 
TAHV/58/CZ-cl  ....................T........EG.S................................L.V..V..................S.......V..  
SSHV/59/MT              ..............................S..................................M.....................L...I........  
LACV/78/NC-cl  ..............................S....I..........................S........................L...I......K.  
JCV/61/CO-cl  ....L.................S......HQ...........................NYQN.IE.N...T.A...D........F............TT  
INKV/64/FI              ....I.................P......HQ..........................RNYQS.IE.N.K.T.A............F.............T  
Consensus   KEVIVRKCFDNDYQACKFLQSPASYRLEEDXGTVTVIDYKKILGTIKMKAILGDVKYKTFADNVDITAEGSCTGCINCFENIHCELTIHTTVEASCPIVS  1300
 
TAHV/58/CZ-cl  ...................I..I.N....P..P....SA.T..A...A.................K.....................F............  
SSHV/59/MT              T.........V.............T....N..TIR.....VE..LA................A.....................................  
LACV/78/NC-cl  ..........V..........M..T....N..TI.V.....E...A................A....................L................  
JCV/61/CO-cl  E.VS.........D.......I..HD..KVS.K......NV..A..I..S..................................................  
INKV/64/FI              DWVS.........D..........Q...KLS.K......N......V..S.................R................................  
Consensus   SCTVFHDRILITPNEHKYALKVVCXEKPGXTLXFKICNTKIDASMTLVDAKPILELAPVDQTTYIREKDERCKTWMCRVRDEGFQVILEPFKNLFGSYIG  1400
 
TAHV/58/CZ-cl  ........LM.IF.....V.........................  
SSHV/59/MT              ..............I...V............K............  
LACV/78/NC-cl  .........V...AI..VL.........................  
JCV/61/CO-cl  ....G.L...C....V......................K.....  
INKV/64/FI              ....G.LC.VC.....................L.....K.V...  
Consensus   IFYTFIISIIALLIVIYIILPICFKLRDTLRQHEDAYKREMKIR  1444 
 
Figure 4 Alignment of the M polyproteins of TAHV/58/CZ-cl, SSHV/59/MT, LACV/78-cl, JCV/61/CO-cl, and INKV/64/FI. Sequence identical
to the consensus indicated with a (.), areas where no consensus exist indicated by (X).
Table 6 Amino acid identity of the orthobunyavirus
predicted protein products compared to TAHV/58/CZ-cl(1)
Percent amino acid identity with TAHV/58/CZ-cl(1)
Virusa N NSs M poly GN NSM GC L
LACV 86 71 79 93 75 76 89
SSH 88 71 81 92 75 79 90
JCV 84 70 72 88 65 69 83
INKV 85 70 72 87 65 69 82
a GenBank accession numbers shown in Table 5.
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available, especially those collected from humans, addi-
tional full genome sequences can be determined, and a
more extensive analysis can be performed. We have
shown using our collection of rhesus immune serum
that virus cross neutralization is not uncommon, and
this has several important implications. Cross-neutrali-
zation may complicate diagnosis and virus identification
based on serology, especially in the case of JCV since
antibodies elicited by JCV readily cross neutralize both
LACV and TAHV. Future diagnostics may need to
L polymerase 
TAHV/58/CZ-cl  ..............T.....I.................K..........................T....V............VD....L..........  
SSHV/59/MT  ...................................F..K.............................................................  
LACV/78/NC-cl  ..Y...........T..................................................V....................V.............  
JCV/61/CO-cl  ..NT...................................................V..L.....D.....L.I..........LD...............  
INKV/64/FI  ..NT................................................I..V..L...K.D.....LEI..........L................  
Consensus   MDHQEYQQFLARINAARDACVAKDIDVDLLMARHDYFGRELCKSLNIEYRNDVPFIDIILDIRPEIDPLTIDAPHITPDNYLYINNILYIIDYKVSVSNE  100 
 
 
TAHV/58/CZ-cl  ..I..............R.M..E.....V......KE.....N.......A.......D.......................S............E...D  
SSHV/59/MT  .................A....P........................I.................K................................A.  
LACV/78/NC-cl  .................D..S.P.................N..........I................................................  
JCV/61/CO-cl  ..I..NT..F.M....A.V.GLH....V.....I....Y.......D.F.................A................................Q  
INKV/64/FI  .....NT..F.M....A.A..LH..........I....Y.........F.................A................................Q  
Consensus   SSVITYDKYYELTRDISSRLNIXIEIVIIRIDPVSRDLHISSDRFKELYPTLVVDINFNQFFDLKQLLYEKFGDDEEFLLKVAHGDFTLTAPWCKTGCPE  200 
 
 
TAHV/58/CZ-cl  ............................................................D....................D..I..I....N.T....E  
SSHV/59/MT  .......................D..R.............V.V..........Y.S....N.................D..T......Q...........  
LACV/78/NC-cl  ........................................V...........EH.S....N....S...............T......QD..........  
JCV/61/CO-cl  V.Q........L.............M...S...................E.N.........V.....N......S..L....M......Q...V.N.I..  
INKV/64/FI  V.Q............I.........MR..S...........RV......E.D..V......V.....D......G..L....M......Q...V...I..  
Consensus   FWKHPIYKEFKMSMPVPERRLFEESVKFNAYESERWNTNLIKIREYTKKDYSDFITKSAKEIFLATGFYKQPNKNEISEGWELMVERVHEQREISKSLHD  300 
 
 
TAHV/58/CZ-cl  ....M.....P........S...................................R........E...N...A................T..........  
SSHV/59/MT  .........................................................S....F.V...N........I...........N..........  
LACV/78/NC-cl  ....................................I....................I...EF.M...S........I...........N..........  
JCV/61/CO-cl  .........ST...N...................R.N....DS.............I.D......Y...Q..L.............K..D..........  
INKV/64/FI  .........SS...N..........................DS.R...........I........H...Q..Q.............K..D..........  
Consensus   QKPSIHFIWGAHNPGNSNNATFKLILLSKSLQSIKGLSTYTEAFKSLGKMMDIGDKATEYESHCDSLKTKARSSWKQVMNKKLEPKQINXALVLWEQQFM  400 
 
 
TAHV/58/CZ-cl  ....I....NRI..L.................D..DN............VF.........T......P..............Q.......G..E..YQ..  
SSHV/59/MT  ...D.....E.........................DT..........A.M.................D..............S....A..E..E...K..  
LACV/78/NC-cl  I..D....SE........................L............A.M............K....SN...P.........S....A..E......K..  
JCV/61/CO-cl  ..S...N........RD............................N...........I..C.IM..EQ.....N....D...KK.G....N.L.I.TS..  
INKV/64/FI  ..S...N........RD............................N......S....I..C.IM..EQN....N....D...KK.G....N.L.V.TS..  
Consensus   VNNELIDKNDKLKLFKNFCGIGKHKQFKNKMLEDIELSKPKILDFDDENIYLASLTMMEQSKRILSKXSGLKSDNFILNEFGXRIKDCNKXTYDNMHXIF  500 
TAHV/58/CZ-cl  .............................................................V......T..L............................  
SSHV/59/MT  ....................................................................D.I.............................  
LACV/78/NC-cl  ..G.................................................................E.I.............................  
JCV/61/CO-cl  ...F...................................L......................A...N.TD.............N................  
INKV/64/FI  ...............................V...........IY.................A...N.ID.............NS......K........  
Consensus   ETRYWQCISDFSTLMKNILSVSQYNRHNTFRIAMCANNNVFAIVFPSADIKTKKATVVYSIIVLHKEEXNVFNPGCLHGTFKCMNGYISISRAIRLDKER  600 
 
 
TAHV/58/CZ-cl  .........................V.N.......Y...................................................K..........G.  
SSHV/59/MT  ....................D....A.N......................................................................D.  
LACV/78/NC-cl  ....................D....V.S.I.....Y..............................................................D.  
JCV/61/CO-cl  ........................VRLE...T..L............................................................E..N.  
INKV/64/FI  .........................RLD......L............................................................E..N.  
Consensus   CQRIVSSPGLFLTTCLLFKHENPTLXMXDVMNFSIFTSLSITKSVLSLTEPARYMIMNSLAISSNVKDYIAEKFSPYTKTLFSVYMTRLIKNACFDAYXQ  700 
 
 
TAHV/58/CZ-cl  .ER........................V..............................................SD.......................V  
SSHV/59/MT  ..H............................................................I..........C......K.................L  
LACV/78/NC-cl  ..R.......................................................................C......K..................  
JCV/61/CO-cl  ..........................................................................S...SE..R...KDL.......Q...  
INKV/64/FI  ..........................................................................N.......K...KDLA......Q...  
Consensus   RQKVQLRDIYLSDYDITQKGIKDNRELTSIWFPGSVTLKEYLTQIYLPFYFNAKGLHEKHHVMVDLAKTILEIEXEQRENITEIWSTNCTKQTVNLKILI  800 
 
 
TAHV/58/CZ-cl  ........................................................NA...RL..N...R......I.......N...............  
SSHV/59/MT  ......................................................M.SV.......T..........M..A....S........G......  
LACV/78/NC-cl  ........................................................SV.......VQ...M.....M..T....C........E......  
JCV/61/CO-cl  ...........................................I...N.Q....I.YT....NI..................EIG...............  
INKV/64/FI  ......................................................V.YT....NI..................ELG...............  
Consensus   HSLCKNLLADTSRHNHLRNRIENRNNFRRSITTISTFTSSKSCLKIGDFRKEKELQXXKQKKILEIESRKRRLANPLFVSDEQVXLEVGHCNYNMLREAM  900 
 
 
TAHV/58/CZ-cl  .....................K....R...........N.............................................................  
SSHV/59/MT  ....................KE..T..........T..N.............................................................  
LACV/78/NC-cl  ....................KK..T............I..............................................................  
JCV/61/CO-cl  .E.R.............M....QV....T..L.....A..TD..........................................................  
INKV/64/FI  .E.K.............M....QV....T..L.....T..TD.........................................................I  
Consensus   PNYTDYISTKVFDRLYELLDTDVLSDKPVIEQIMDMMVDHKKFYFTFFNKGQKTSKDREIFVGEYEAKMCMYAVERIAKERCKLNPDEMISEPGDGKLKV  1000
                                                                                Premotif A         
 
TAHV/58/CZ-cl  .....................D.....S...S....E.VER.....R..S..................................................  
SSHV/59/MT  .................................GY.A..E......IS..K.........................................Y......E  
LACV/78/NC-cl  ...............................T.GY.S.LG......L...K.........................................Y.......  
JCV/61/CO-cl  .....................G......S..........S.....AK............................................I..F.....  
INKV/64/FI  .......................................S.....AE............................................I..F.....  
Consensus   LEQKSEQEIRFLVETTRQKNREIDEAIEALAAENFEGNIXKIEKLSXGKARGLKMEINADMSKWSAQDVFYKYFWLIALDPILYPQEKERILFFMCNYMQ  1100
                                                                              Motif A   
 
TAHV/58/CZ-cl  .....................................P..................................F..........................T  
SSHV/59/MT  ..................V......T...........P..........................E.....V.L....V.................I...L  
LACV/78/NC-cl  ..................A......A...........L..........................E.......L..........................M  
JCV/61/CO-cl  .K.....D.MC......A..RD....I.....QT.C.E...........................V....MS..E...VI............V......A  
INKV/64/FI  .K.....D.MC......T..KD....V.....QT.Y.E...........................V....MS..E...V.............V......A  
Consensus   KELILPDELLFNLLDQKVTYQNDIISTMTNQLNSNTVXIKRNWLQGNFNYTSSYVHSCAMSVYKDILKEAITYLDGSILVNSLVHSDDNQTSITIVQDKX  1200
                                                               Motif B                               Motif C    
Figure 5 Alignment of the L proteins (aa 1-1200) of TAHV/58/CZ-cl, SSHV/59/MT, LACV/78-cl, JCV/61/CO-cl, and INKV/64/FI. Sequence
identical to the consensus indicated with a (.), areas where no consensus exist indicated by (X). RNA-dependent RNA polymerase conserved
motifs are underlined in the consensus sequence for L protein.
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utilize PCR to differentiate CEV members when virus is
available. When only post-infection serum samples are
available, multiple viruses of the CEV serogroup will
need to be used for neutralization studies. However, the
observed cross neutralization also suggests that a single
vaccine could generate a cross-neutralizing antibody
response which may provide protection against viruses
of the CEV serogroup from a wide geographic range.
Such vaccine candidates are currently under develop-
ment in our laboratory.
L polymerase 
TAHV/58/CZ-cl  T..I......R....S....................................................................................  
SSHV/59/MT  E.DKI.H..MG.........................................................................................  
LACV/78/NC-cl  E.DKI....MK...R.....................................................................................  
JCV/61/CO-cl  PD....E.S.TQ.Q......................................................................................  
INKV/64/FI  PD....E.S.TQ.Q.I..............I.....................................................................  
Consensus   XNEVLIDFAIXEFEKACLTFGCQANMKKTYVTNCIKEFVSLFNLYGEPFSIYGRFLLTSVGDCAYIGPYEDLASRISSAQTAIKHGCPPSLAWVSIAISH  1300
                                            Motif D       Motif E  
 
TAHV/58/CZ-cl  ...Y.......................E.......I..................N...S......................RS....E............  
SSHV/59/MT  ...A..................................................Y........................................R....  
LACV/78/NC-cl  ...S..............................................S...Y......S.................................R....  
JCV/61/CO-cl  .I...............M.........................................M...H..I...........S.IR..DLNRMD..........  
INKV/64/FI  .I...............M......T..................................M...H..I...........S.I...DLSR.D..........  
Consensus   WMTGLTYNMLPGQSNDPIDYFPAENRKDIPIELNGVLDAPLSMISTVGLEAGNLWFLIKLLNKYTPVMQKRESVVNQIAEVKNWKVEDLTDNEIFKLKIL  1400
 
 
TAHV/58/CZ-cl  ....................................................A....E...................S......................  
SSHV/59/MT  ............................................G............L...................MR.....................  
LACV/78/NC-cl  .........................................................V...................M......................  
JCV/61/CO-cl  ..................................S......................N...Q...............KR.....................  
INKV/64/FI  ..................................S......................N...Q...D...........K......................  
Consensus   RYLVLDAEMDPSDIMGETSDMRGRSILTPRKFTTAGSLRKLYSFSKYQDRLSSPGGMXELFTYLLEKPELLVTKGEDXKDYMESVIFRYNSKRFKESLSI  1500
 
 
TAHV/58/CZ-cl  .................................................T.............T...E.......................V........  
SSHV/59/MT  .................................................I.............E..................M.................  
LACV/78/NC-cl  .................................................T.......R.....E.......VI.........M.................  
JCV/61/CO-cl  ..............N............................I.....R....I.....N..P..........................Q.........  
INKV/64/FI  .................I.........................I.....K..........N..P..........................Q.........  
Consensus   QNPAQLFIEQILFSHKPVIDFSGIRDKYINLHDSRALEKEPDILGKVTFXEAYRLLMKDLSSLXLTNDDIQVVYSYIILNDPLMITIANTHILSIYGSPQ  1600
 
 
TAHV/58/CZ-cl  ...........................................................G.....RL...Q..V..........................  
SSHV/59/MT  ...........................................................G..........L..A..........................  
LACV/78/NC-cl  R...................................I.............................V...M..A..........................  
JCV/61/CO-cl  ..T..............................T...........S..........D....RT..EK...E......A....................I.  
INKV/64/FI  ..T..............................T..IQ.......S......R...D....RL..EK..SD......A....................I.  
Consensus   KRMGMSCSTMPEFRNLKLIHHSPALVLRAYSKNNPDVQGADPTEMARDLVHLKEFVENTNLEEKMKIRIAXNELEKGQRDIVFELKEMTRFYQVCYEYVK  1700
TAHV/58/CZ-cl  ......................A................................................V.......E.S..........EQ......  
SSHV/59/MT  ..............S.................................................................SS...........E......  
LACV/78/NC-cl  ..............S.................................................................SL.........I.E......  
JCV/61/CO-cl  ........................................................S...........R............G..PA....V..S......  
INKV/64/FI  ........................................................S...........R............G..P........S......  
Consensus   STEHKIKVFILPAKAYTTTDFCSLMQGNLIKDKEWYTVHYLKQILSGGHKAIMQHNATSEQNIAFECFKLITHFADSFIDAXSRSAFLQLILDXFSYKDV  1800
 
 
TAHV/58/CZ-cl  R.H...........................T............................V........................................  
SSHV/59/MT  ..A...........................S........................................................L............  
LACV/78/NC-cl  ..S.........Y...............R.A............................S...........................L............  
JCV/61/CO-cl  ..N...E.....................T.Y..........Q.......................S....A............S..NI........S...  
INKV/64/FI  R.N...E.....................T.H..........Q.......................N....A............S..NI........S...  
Consensus   KVXKLYDIIKNGHNRTDFIPLLFRTGDLKQXDLDKYDAMKSHERVTWNDWQTSRHLDMGAINLTITGYNRSITIIGEDNKLTYAELCITRKTPENITISG  1900
 
 
TAHV/58/CZ-cl  ..................P.........F........................................V..................F....V.T....  
SSHV/59/MT  ..................Q.................F....................K...Y.......I.......................V......  
LACV/78/NC-cl  ....G..........S..Q.................F........................Y.......V...............S..............  
JCV/61/CO-cl  .................VT..................I....T....L.................V.........I.....................A..  
INKV/64/FI  .................VT..................I....T....L........................I..I.....................AK.  
Consensus   RKLLSSRHGLKFENMAKIXTYPGNYYITYRKKDRHQYVYQIHSHESITRRNEEHMAIRTRIFNEITPVCLVNVAEVDGDQRILIRKLDYLNNDIFSLSRI  2000
 
 
TAHV/58/CZ-cl  ...................................................................ED...................S...........  
SSHV/59/MT  ...LE...................................................................................A...........  
LACV/78/NC-cl  ...L.................E................................................N.................A...........  
JCV/61/CO-cl  ......Y.V......................N............................I.....T....E..........A.................  
INKV/64/FI  ......Y.V......................N............................I.....T....E..........A.................  
Consensus   KVGIDEFATIKKAHFSKMVSFDGPPIKTGLLDLTELMKSQDLLNLNYDNIRNSNLISFSKLICCEGSDNIDDGLEFLSDDPMNFTEGETIHSTPIFNIYY  2100
 
 
TAHV/58/CZ-cl  .....S.........Q..D...LS........T....................I...D........................A..I....V....N.KVD  
SSHV/59/MT  .............V........KV........S...................K................................V....ME...T.D..  
LACV/78/NC-cl  ......................KI........E..............V....K................................V....MG...T.D..  
JCV/61/CO-cl  ..K...................SN.......YKD..L...........I....V.....................N..YL..K....S....D....N..  
INKV/64/FI  ......................DK.......YKD..L...........I....V.....................N..YL..R....S....D....N..  
Consensus   SKRGERHMTYRNAIKLLIERETXXFEEAFTFSXNGFISPENLGCLEAIVSLIRLLKTNEWSTVIDKCIHICLIKNGMDHMYHSFDMPKCFIDNPISRXIN  2200
 
 
TAHV/58/CZ-cl  .........N..T.RV......MD.......................VQ........G.....  
SSHV/59/MT  .......V....S.D..................................L.........I...  
LACV/78/NC-cl  ............G.D.......T..............F.........T.L.........I...  
JCV/61/CO-cl  .L...D..ST..P.Y.A...I...H.RT..ST..MD.M....N.QD.....RRSE..T..D.S  
INKV/64/FI  .L...D..ST..P.YVA...I.....RT..SM..MD.M....N.QD.....RRSE..T..D.N  
Consensus   WVMYREFINSLPXTXIPPWNVMLENFKKKCIALINSKLETQRDFSEFAKMMKKEGGRSNLEFD  2263
Figure 6 Alignment of the L proteins (aa 1201-2263) of TAHV/58/CZ-cl, SSHV/59/MT, LACV/78-cl, JCV/61/CO-cl, and INKV/64/FI .
Sequence identical to the consensus indicated with a (.), areas where no consensus exist indicated by (X). RNA-dependent RNA polymerase
conserved motifs are underlined in the consensus sequence for L protein.
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NSS
TAHV/58/CZ-cl  .....P..........M.T...N.GKQL.SI........................V.........S.............I........C.G.WLDGC  
SSHV/59/MT  ....Q.................N.Q.Q..L.Q.....S...R.R...R..Q...QI....................I..TA......DC...----- 
LACV/78/NC-cl  ....Q.............T...K.Q.H.TL.Q.....S...R.R...R..Q....T...............................DYLG.-----  
JCV/61/CO-cl  ............Q...L..LW.TTESL..CQ........Q.........N.S.K...S.......S....................I.....-----  
INKV/64/FI  ..L.........Q...L..LW.T.E.L..WQ........Q.........N.S.K...................................L..-----  
Consensus   MMSHPQVQMDLILMQGIWHSVLXMXNXSIXLPLGSSSLMPQKPKLLSLVSRRGRLLLNLESGRWRLSIIIFLETGTTQLVTTILPSTGFQDIXXXXX  97   
 
N
TAHV/58/CZ-cl  ........................D..I....A...HS.......................S.......................D..............  
SSHV/59/MT  .......................M.....YA..V...................S.......N.......................NSD............  
LACV/78/NC-cl  .......................MD....NA..L...................S.......N..........I...........................  
JCV/61/CO-cl  .G....................F...MAD.......S..................................I.....S......................  
INKV/64/FI  .G....................F...MAD..........................................I............................  
Consensus   MSDLVFYDVASTGANGFDPDAGYVAFCVKHGESINLAAVRIFFLNAAKAKAALARKPERKATPKFGEWQVEVVNNHFPGNRNNPIGNNDLTIHRLSGYLA  100
 
TAHV/58/CZ-cl  .......K....AA.....K..V..........R....A....A...........................................S...........T  
SSHV/59/MT  ......YK..E...R....K............VR..S.A................................................S..........VT  
LACV/78/NC-cl  ....D.YN.......H................VG..S............................H................................VA  
JCV/61/CO-cl  .....H.NSD..........S............H.N..................I..............H.....................E...A...V  
INKV/64/FI  .....H.T.D..........S............H.N..................V..............H.....................E...A...V  
Consensus   RWVLEQF*ENDDESQRELIRTTIINPIAESNGI*WDNGPEIYLSFFPGTEMFLETFKFYPLTIGIYRVKQGMMDPQYLKKALRQRYGTLTADKWMSQKT*  200
 
TAHV/58/CZ-cl  ...................................  
SSHV/59/MT  .......E................S..........  
LACV/78/NC-cl  ............R..K.......K...........  
JCV/61/CO-cl  L....................A.....I...VK..  
INKV/64/FI  L....................A.....I...VK..  
Consensus   AIAKSLKDVEQLKWGRGGLSDTARTFLQKFGIRLP  235  
Figure 7 Alignment of the N and NSS proteins of TAHV/58/CZ-cl, SSHV/59/MT, LACV/78-cl, JCV/61/CO-cl, and INKV/64/FI. Sequence
identical to the consensus indicated with a (.), areas where no consensus exist indicated by (X).
Table 7 TAHV is antigenically distinct from LACV and JCV by cross neutralizing antibody assay
Immunizing virusa Serum neutralizing antibody titer against indicated virusb
Monkey # LACV/78/NC-cl JCV/61/CO-cl TAHV/58/CZ-cl
LACV/78/NC-cl DB70 2077 <10 383
DB8N 222 <10 <10
CK74 2782 <10 80
CL2G 326 <10 <10
DBCZ 4728 <10 169
CL6E 3719 <10 <10
DB0H 364 <10 <10
DA9F 1374 <10 82
GMTc: 1177 <10 36
JCV/61/CO-cl A5E054 77 457 <10
A5E060 2825 352 282
A5E068 106 221 50
A5E069 85 712 168
A5E070 192 662 27
A5E073 140 256 49
A5E077 243 685 106
DBXG 107 407 163
GMT: 185 431 69
TAHV/58/CZ-cl DBPN 92 14 1698
DBM6 58 <10 494
A5E006 15 <10 360
DBXJ 339 31 3195
A5E036 113 <10 316
L27 15 <10 215
DC11 151 <10 1613
GMT: 68 11 725
a Monkeys were immunized subcutaneously with 5 log10 PFU of indicated virus and serum was collected on day 28.
b Reciprocal PRNT60 assayed against indicated virus. Lower limit of detection is 10.
b Geometric mean titer. For the purpose of calculation, a value of 9 was assigned to monkeys with titers less than 10.
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Materials and methods
Cells culture
C6/36 cells (Aedes albopictus) were maintained in Ear-
le’s MEM supplemented with 10% fetal bovine serum
(HyClone, Logan, UT), 2 mM L-glutamine (Invitrogen,
Grand Island, NY), and 1 mM non-essential amino acids
(Invitrogen). Vero cells (African green monkey kidney)
were maintained in OptiPRO™SFM medium (Invitro-
gen) supplemented with 4 mM L-glutamine.
Isolation of biologically-cloned viruses
Terminal dilution in Vero cells was used to prepare biolo-
gical clones TAHV/58/CZ-cl(1), TAHV/68/FR-cl, and
TAHV/84/CZ-cl. Virus stocks were serially diluted in 2-
fold increments and inoculated onto 90% confluent mono-
layers of Vero cells in 96-well plates using eight wells per
dilution. After five days of incubation at 37°C, cell culture
fluid was removed to a holding plate, and the cell mono-
layers were fixed and stained for 10 minutes with crystal
violet solution (1% crystal violet in equal volumes of etha-
nol and methanol). The virus was selected as a clonal deri-
vative when only 1 or 2 of the 8 wells in a single row was
positive for TAHV CPE. Each virus was terminally diluted
three times (sequentially), amplified in Vero cell culture,
and subjected to genome sequence analysis. TAHV/58/CZ
also underwent three rounds of plaque purification and a
single round of amplification in Vero cells to generate
TAHV/58/CZ-cl(2). For plaque purification, six-well plates
with confluent monolayers of Vero cells were infected
with serial dilutions of TAHV/58/CZ, and the virus was
allowed to attach for one hour. Excess inoculum was
removed and cells overlayed with equal volumes of 1.6%
SeaPlaque agarose and 2X MEM (Invitrogen) supplemen-
ted with 10% FBS and 4 mM glutamine. Plaques were
allowed to develop for 4 days, and the wells were overlaid
with an additional 2 mL of 1.6% SeaPlaque agarose con-
taining 4% v/v neutral red solution (3.3 g neutral red/L
PBS, Sigma Aldrich, St. Louis). After the third plaque pick,
virus was amplified in Vero cells.
RNA Isolation and sequencing
Viral RNA was isolated using either QIAamp Viral RNA
kit (Qiagen, Valencia, CA) or High Pure Viral Nucleic
Acid Large Volume Kit (Roche, Indianapolis, IN). Over-
lapping PCR fragments were generated using Titan One
Tube RT-PCR Kit (Roche) using TAHV or LACV speci-
fic primers. PCR fragments were purified and both
strands directly sequenced using viral-specific primers in
BigDye-terminator cycle sequencing reactions analyzed
on an ABI3730 genetic analyzer (Applied Biosystems,
Foster City, CA). Sequence fragments were assembled
into a consensus sequence using AutoAssembler 2.1
software (Applied Biosystems).
To sequence the 5’ and 3’ genome ends of TAHV/58/
CZ, viral RNA was isolated using QIAamp Viral RNA
kit (Qiagen) from virus infected cells at 24-48 hours
post infection for the 3’ untranslated region (UTR) or
from clarified cell culture fluid for the 5’ UTR. Viral
RNA was reverse transcribed using Reverse Transcriptor
(Roche) at 55°C with random hexamer primers for the
5’ UTR or with genome-specific primers for the 3’ UTR
held at 60-70°C to enhance reverse transcription though
RNA secondary structures. cDNA was purified with
High Pure PCR product purification kit (Roche) and a
poly-A tail was added to the 3’ end of the cDNA using
5’/3’ RACE Kit, Second Generation (Roche). Genome
ends were then amplified using virus and poly-A specific
primers. Purified PCR fragments were sequenced as
described above.
Once the first and last 13 nucleotides of TAHV/58/CZ
were confirmed to be identical to the known consensus
sequence for all orthobunyaviruses, primers that had a
known sequence abutted to the 13 nucleotide consensus
sequence were generated: primer 1(forward) 5’-gaccatc-
tagcgacctccacagtagtgtact- 3’ and primer 2 (reverse)
5’-gaccatctagcgacctccacagtagtgtgct-3’ (underlined
sequence corresponds to genome terminii). These con-
sensus primers were used to determine the 3’ and 5’
UTR sequence of all remaining TAHV isolates.
Viral growth kinetics in tissue culture
TAHV/58/CZ-cl(1), TAHV/58/CZ-cl(2), TAHV/68/FR-
cl, and TAHV/84/CZ-cl were used to infect 95% conflu-
ent monolayers of C6/36 or Vero cells in triplicate, at a
multiplicity of infection of 0.01 and incubated for one
hour to allow attachment. Infected monolayers were
washed three times with sterile PBS and overlaid with
medium. Tissue culture supernatant (0.5 mL) was col-
lected at times 0, 8, 16, 24, 32, 40, 48, and 72 hours
after infection, mixed with one-tenth volume of 10X
SPG buffer (final concentration 218 mM sucrose, 6mM
L-glutamic acid, 3.8 mM dibasic potassium phosphate,
pH 7.2), and frozen for later titration.
TAHV clinical disease in mice
The lethal dose50 (LD50) of TAHV was evaluated in
Swiss Webster weanling mice (Taconic Farms,
Table 8 Percent relatedness between LACV, JCV, and
TAHV
% Relatednessa
Viruses compared LACV/78/NC-cl JCV/61/CO-cl TAHV/58/CZ-cl
LACV/78/NC-cl - 5.7 5.8
JCV/61/CO-cl 5.7 - 4.9
TAHV/58/CZ-cl 5.8 4.9 -
a Percent relatedness = (r1 * r2)
1/2 * 100, where r1 is the geometric mean
neutralization titer of antibody 1 to homologous strain 1, and r2 is the
geometric mean neutralization titer of antibody 2 to heterologous strain 1/
geometric mean neutralization titer of antibody 2 to homologous strain 2.
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Germantown, NY). All animal experiments were car-
ried out in accordance with the regulations and guide-
lines of the National Institutes of Health. Twenty-one
to twenty-three day-old mice (n = 6/dose) were inocu-
lated with serial dilutions of wildtype or biologically-
cloned TAHV in a volume of 10 μL intracerebrally
(IC) or 100 μL intraperitoneally (IP). Mice were
anesthetized with isofluorane prior to IC inoculation.
Following inoculation, all mice were carefully observed
twice daily for clinical disease including tremors, sei-
zures, and limb paralysis. Because clinically moribund
mice were humanely euthanized before succumbing to
infection, moribundity served as a surrogate for the
determination of lethality. For determination of the
infectious dose50 (ID50), mice were considered infected
if they exhibited clinical disease or developed a detect-
able serum neutralizing antibody titer.
Inoculation of rhesus monkeys
Eight sero-negative rhesus monkeys were inoculated
subcutaneously with 105 PFU of biologically-cloned
TAHV/58/CZ-cl(1). Serum samples were collected and
frozen on days -7, 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, and 42
post inoculation for determination of viremia and neu-
tralizing and cross-neutralizing antibody titer. Monkeys
were observed daily for clinical disease.
Neutralization assay
Neutralizing antibody in mouse and monkey serum
was quantified by a plaque reduction neutralization
assay. Test sera were heat inactivated (56°C for 30
minutes) and serial 2-fold dilutions beginning at 1:10
were prepared in OptiMEM (Invitrogen) supplemen-
ted with 2% FBS, 50 μg/mL gentamicin, and 0.5%
human albumin (Talecris Biotherapeutics, Inc.,
Research Triangle Park, NC). The virus (TAHV, JCV,
or LACV) was diluted to a final titer of 500 PFU/mL
in the same diluent and 10% guinea pig complement
(Cambrex Bioscience Walkersville, Inc., Walkersville,
MD) was added to equal volumes of the serum dilu-
tions and mixed well. Serum/virus mixture was incu-
bated at 37°C for 30 minutes, added to confluent
monolayers of Vero cells, and incubated for 1 hour
to allow virus attachment. Cells were overlayed with
1% methylcellulose and incubated for 5 days at 37°C.
To visualize plaques, the overlay was removed, and
cell monolayers were washed twice with PBS and
immunostained with anti-LACV antibody18752 (QED
Bioscience, San Diego, CA) which recognizes JCV,
LACV, and TAHV. A 60% plaque-reduction neutrali-
zation titer was calculated. Antigenic relatedness was
determined using the method of Archetti and Hors-
fall [27].
Additional material
Additional file 1: TAHV predicted protein alignment. Sequence
identical to the consensus is indicated with a (.), and the areas where no
consensus exists are indicated by (X). Unique amino acid differences
between neuroinvasive TAHV/58/CZ-cl(1) and the consensus sequence
are identified with an arrow (↓).
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